Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Targeted therapies associated with increased risk for and incidence of...

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

The use of IORT at L'Hospitalet de Llobregat

Dr Evelyn Martínez Pérez - Catalan Institute of Oncology, Barcelona, Spain

The use of IORT at L'Hospitalet de Llobregat ( Dr Evelyn Martínez Pérez - Catalan Institute of Oncology, Barcelona, Spain )

Understanding intraoperative radiation therapy for early stage breast cancer

Dr Jana Fox - Montefiore Medical Center, New York,USA

Understanding intraoperative radiation therapy for early stage breast cancer ( Dr Jana Fox - Montefiore Medical Center, New York,USA )

The use of IORT at Montefiore Medical Center

Dr Sheldon Feldman - Montefiore Einstein Comprehensive Cancer Center, New York...

The use of IORT at Montefiore Medical Center ( Dr Sheldon Feldman - Montefiore Einstein Comprehensive Cancer Center, New York, USA )

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC...

Dr Nan Chen - The University of Chicago, Chicago, USA

Patients with early-stage, HR+/HER2-negative BC may benefit from adjuvant T-AC therapy more than from TC ( Dr Nan Chen - The University of Chicago, Chicago, USA )

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not...

Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK

Postmastectomy radiotherapy in 'intermediate-risk' breast cancer does not impact overall survival ( Prof Ian Kunkler - University of Edinburgh, Edinburgh, UK )

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in...

Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron...

HER3-DXd demonstrates similar efficacy compared to multi-agent chemotherapy in high-risk HR-positive/HER2-negative eBC ( Dr Mafalda Oliveira - Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk...

Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA

Post-chemo olaparib continues to improve efficacy in gBRCApv and high-risk, HER2-negative primary breast cancer ( Dr Judy Garber - Dana-Farber Cancer Institute, Boston, USA )

Immediate breast surgery versus deferral of surgery in women aged 70+ years...

Prof Robert Hills - University of Oxford, Oxford, United Kingdom

Immediate breast surgery versus deferral of surgery in women aged 70+ years with operable breast cancer ( Prof Robert Hills - University of Oxford, Oxford, United Kingdom )

Teclistamab-lenalidomide and teclistamab alone can be safely administered as...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...

Dr Adam Olszewski - Brown University, Providence, USA

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )

Acalabrutinib plus venetoclax with or without obinutuzumab versus...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer